Form 4: Northrop Grumman Exec Sells Shares After RSR Vesting
Insider Transaction Report
Roshan S. Roeder, CVP & President of Mission Systems at Northrop Grumman, reported the vesting of restricted stock rights and subsequent sale of common stock.
Summary
- Roshan S. Roeder, CVP & President of Mission Systems, reported transactions on February 17, 2026.
- 2,017 Restricted Stock Rights (RSRs) vested and converted into an equivalent number of common stock shares. These RSRs were granted on February 16, 2023.
- Following the vesting, 992 shares of common stock were disposed of at $701.12 per share, likely for tax withholding purposes.
- An additional 318 shares of common stock were sold at $702.56 per share, executed under a Rule 10b5-1 trading plan adopted on October 30, 2025.
- After these transactions, Roeder directly owns 4,619.39 shares of common stock and indirectly owns 115.9291 shares in the Northrop Grumman Savings Plan.
- Roeder also holds 6,513 unvested Restricted Stock Rights with future vesting dates in 2027, 2028, and 2029.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The vesting of RSRs is a positive for the executive, reflecting earned compensation, and the sales are largely routine for tax purposes and under a pre-planned schedule, which typically does not signal negative sentiment about the company's future.
Positives
- Vesting of 2,017 Restricted Stock Rights indicates successful achievement of performance or time-based conditions.
- The existence of a Rule 10b5-1 trading plan demonstrates a pre-planned and transparent approach to insider stock sales.
Negatives
- A net reduction in direct common stock holdings by 318 shares through a sale, in addition to shares disposed for tax withholding.
Future Outlook
The filing details future vesting schedules for 6,513 Restricted Stock Rights, indicating continued long-term incentive alignment for the reporting person through February 2029.
Industry Context
StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine part of executive compensation and wealth management strategies in the defense and aerospace industry. While these sales represent a reduction in direct holdings, the pre-planned nature typically mitigates concerns about immediate negative sentiment, distinguishing them from opportunistic sales.
Comparison to Industry Standards
- StockSavvy.ai observes that the use of Restricted Stock Rights (RSRs) as a component of executive compensation, followed by sales for tax purposes and under 10b5-1 plans, is a standard practice across major defense contractors such as Lockheed Martin (LMT), Raytheon Technologies (RTX), and Boeing (BA).
- The vesting of RSRs aligns executive incentives with long-term company performance, a common benchmark in the industry.
- The reported transaction prices of $701.12 and $702.56 per share are specific to Northrop Grumman's stock performance at the time of the transaction and are not directly comparable to other companies' stock prices without context of their respective market valuations.
Related Party Transactions
- The reported transactions are insider dealings by a corporate officer, which are a form of related party transaction.
- The acquisition of shares through the vesting of Restricted Stock Rights is part of the executive compensation plan.
- The indirect holding of shares in the Northrop Grumman Savings Plan represents a related party investment vehicle.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive, even if pre-planned, could be perceived as a slight reduction in insider alignment, though the remaining significant holdings and future RSRs mitigate this.
- Employees: The vesting of RSRs demonstrates the company's commitment to its long-term incentive plans for executives.
Next Steps
- Vesting of 2,356 RSRs on February 16, 2027.
- Vesting of 2,456 RSRs on February 18, 2028.
- Vesting of 1,701 RSRs on February 12, 2029.
Key Dates
| Date | Description |
|---|---|
| 2023-02-16 | Grant date of 2,017 Restricted Stock Rights under the 2011 Long-Term Incentive Stock Plan. |
| 2024-02-14 | Grant date of 2,356 Restricted Stock Rights under the 2011 Long-Term Incentive Stock Plan. |
| 2025-02-18 | Grant date of 2,456 Restricted Stock Rights under the 2024 Long-Term Incentive Stock Plan. |
| 2025-10-30 | Adoption date of Rule 10b5-1 trading plan by the reporting person. |
| 2026-02-11 | Grant date of 1,701 Restricted Stock Rights under the 2024 Long-Term Incentive Stock Plan. |
| 2026-02-17 | Transaction date for vesting of RSRs and subsequent stock dispositions. |
| 2026-02-19 | Filing date of the Form 4 statement. |
| 2027-02-16 | Vesting date for 2,356 Restricted Stock Rights granted on 2/14/24. |
| 2028-02-18 | Vesting date for 2,456 Restricted Stock Rights granted on 2/18/25. |
| 2029-02-12 | Vesting date for 1,701 Restricted Stock Rights granted on 2/11/26. |
Recommendation
holdThis Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of restricted stock and subsequent sales for tax purposes and under a pre-arranged 10b5-1 plan. Such transactions are generally expected and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment strategy. The executive retains significant holdings and future RSRs, maintaining alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.
Keywords
Northrop Grumman, NOC, Insider Trading, Form 4, Stock Sale, Restricted Stock Rights, Executive Compensation, Rule 10b5-1, Roshan S. Roeder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.